The role of miRNA-15a in diagnostics of renal cell carcinoma


Ю. О. Мицик
В. Є. Досенко
Ю. Б. Борис
Т. І. Древицька


Renal cell carcinoma (RCC) – is the most common primary tumor of the kidney. The part of nondiagnostic percutaneous core biopsy (PCB) of the kidney varies from 5 to 40%. The application of imaging methods of examination, such as CT or MRI don’t guarantee 100% sensitivity and specificity for diagnosis of RCC, remaining within 88–96%.
The objective: the goal of the investigation was to estimate the value of application of the miRNA-15a expression in urine as a biomarker of RCC.
Patients and methods. The study enrolled 67 adult patients with solid renal neoplasms: RCC (n=58), benign renal tumors (n=15). The medium age was 60,19±6,36 years, the medium size of the tumor was 7,01±2,08 sm. All patients were treated by surgery. One day before and after the 8th day after the surgery in all patients and once in 30 healthy volunteers without renal pathology 100–150 ml of urine was collected with further definition of expression by using reverse transcription and PCR in real time.
Results. For the first time significant difference (р<0,05) was detected between medium values of miR-15a expression in urine of the patients with RCC, benign renal tumors and healthy people: 2,50E-01±2,72E-01 УО vs 1,32E-03±3,90E-03 vs 3,36E-07±1,04E-07 УО accordingly. The strong correlation between the size of RCC and the level of miR-15a expression was observed (r=0,87). The sensitivity and specificity during differentiation of RCC and benign renal tumors using the threshold 03±5,18E-03 УО were 98,1% and 100% accordingly.
Conclusion. Application measured in urine miR-15a expression may be used as a biomarker of RCC. Further studies are required with inclusion of bigger quantity of patients with different histological subtypes of RCC and grades of differentiation, benign renal tumors for more depth analysis of diagnostic value of miR-15a Further studies are needed for finding out the reason of miR-15a upregulation in urine of the patients with RCC, considering its tumor-protective features, which are described in literature.


How to Cite
Мицик, Ю. О., Досенко, В. Є., Борис, Ю. Б., & Древицька, Т. І. (2017). The role of miRNA-15a in diagnostics of renal cell carcinoma. Health of Man, (3(62), 110–115.
Author Biographies

Ю. О. Мицик, Львівський національний медичний університет імені Данила Галицького

Yu. Mytsyk

В. Є. Досенко, Інститут фізіології імені О.О. Богомольця НАН України, м. Київ

V. Dosenko

Ю. Б. Борис, Львівський національний медичний університет імені Данила Галицького

Yu. Borys

Т. І. Древицька, Інститут фізіології імені О.О. Богомольця НАН України, м. Київ

T. Drevytska


Pierorazio Phillip M., Michael H. et al. Management of Renal Masses and Localized Renal Cancer: Systematic Review and Meta-Analysis // The Journal of Urology. – 2016. – Vol. 196, No 4. – P. 989–99.

Blute Michael, Joel Prince, Eric Bultman et al. Predictors of non-diagnostic renal mass biopsy // The Journal of Urology. – 2015. – Vol. 193. No 4. – Р. 532–533.

Menogue Stuart R., Beverley A. O’Brien, Alexandra L. Brown et al. Percutaneous Core Biopsy of Small Renal Mass Lesions: A Diagnostic Tool to Better Stratify Patients for Surgical Intervention // BJU International. – 2013. –Vol. 111, No 4. – Р. 146–151.

Zhang Hanmei, Qi Gan, Yinghua Wu et al. Diagnostic Performance of Diffusion-Weighted Magnetic Resonance Imaging in Differentiating Human Renal Lesions (Benignity or Malignancy): A Meta-Analysis // Abdominal Radiology. – 2016. – Vol. 41, No10. – P. 1997–2010.

Kim See Hyung, Chan Sun Kim, Mi Jeong Kim et al. Differentiation of Clear Cell Renal Cell Carcinoma From Other Subtypes and Fat-Poor Angiomyolipoma by Use of Quantitative Enhancement Measurement During Three-Phase MDCT // American Journal of Roentgenology. – 2016. – Vol. 206, No 1. – P. 21–28.

Fujii Y., Saito K., Iimura Y. et al. Incidence of Benign Pathologic Lesions at Nephrectomy for Renal Masses Presumed to Be Stage I Renal Cell Carcinoma in Japanese Patients: Impact of Sex, Age, and Tumor Size // ASCO Meeting Abstracts. – 2011. – No 7 (29). – Р. 374.

Строй О.O., Банира О.Б., Шуляк О.В. Цінність Мікро-РНК-508-3р у діагностиці раку нирки // Український Медичний Часопис. – 2012. – No 2. – С. 1–3.

Chen Xuanyu, Xuegang Wang, Anming Ruan et al. MiR-141 is a Key Regulator of Renal Cell Carcinoma Proliferation and Metastasis by Controlling EphA2 Expression. Clinical Cancer Research. – 2014. – No 10 (20). – P. 2617–30.

Vergho Daniel, Susanne Kneitz, Andreas Rosenwald et al. Combination of Expression Levels of miR-21 and miR-126 Is Associated with Cancer-Specific Survival in Clear-Cell Renal Cell Carcinoma // BMC Cancer. – 2014. – No 14 (25). – P. 1–10.

Teixeira Ana L., Marta Ferreira, Joana Silva et al. Higher Circulating Expression Levels of miR-221 Associated with Poor Overall Survival in Renal Cell Carcinoma Patients // Tumour Biology. – 2014. – No 5 (35). – P. 4057–66.

Iwamoto Hideto, Yusuke Kanda, Takehiro Sejima et al. Serum miR-210 as a Potential Biomarker of Early Clear Cell Renal Cell Carcinoma // International Journal of Oncology. – 2014. – No 1 (44). – P. 53–58.

Spek A., Szabados B., Ziegelmьller B. et al. Clinical Usage of Different Guidelines in Routine Management, Therapy and Follow-Up of Patients with Renal Cell Cancer in Germany // Urologia Internationalis. – 2016. – No 1. – P. 1–5.

Terzuoli Erika, Sandra Donnini, Federica Finetti et al. Linking Microsomal Prostaglandin E Synthase-1/PGE-2 Pathway with miR-15a and -186 Expression: Novel Mechanism of VEGF Modulation in Prostate Cancer // Oncotarget. – 2016. – No 1. – P. 2–6.

Zhu Kang, Ying He, Cui Xia et al. MicroRNA-15a Inhibits Proliferation and Induces Apoptosis in CNE1 Nasopharyngeal Carcinoma Cells // Oncology Research. – 2016. – No 3 (24). – P. 145–51.

Gao Shen-Meng, Chong-Yun Xing, Chi-Qi Chen. et al. MiR-15a and miR-16-1 inhibit the Proliferation of Leukemic Cells by down-Regulating WT1 Protein Level // Journal of Experimental & Clinical Cancer Research. – 2011. – No 30. – P. 110.

Alderman Christopher, Ayoub Sehlaoui, Zhaoyang Xiao et al. MicroRNA-15a inhibits the Growth and Invasiveness of Malignant Melanoma and Directly Targets on CDCA4 Gene // Tumour Biology. – 2016. – No 4. – P. 1–6.

Xie T., Liu P., Chen L. et al. MicroRNA-15a down-regulation is Associated with Adverse Prognosis in Human Glioma // Clinical & Translational Oncology. – 2015. – No 7 (17). – P. 504–10.

Shinden Yoshiaki, Sayuri Akiyoshi, Hiroki Ueo et al. Diminished Expression of MiR-15a Is an Independent Prognostic Marker for Breast Cancer Cases // Anticancer Research. – 2015. – No 1 (35). – P. 123–27.

Brandenstein Melanie, Jency J. Pandarakalam, Lukas Kroon et al. MicroRNA 15a, Inversely Correlated to PKCб, Is a Potential Marker to Differentiate between Benign and Malignant Renal Tumors in Biopsy and Urine Samples // The American Journal of Pathology. – 2012. – No 5 (180). – P. 1787–97.